Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Joshua Rabinowitz
Princeton University, Department: None
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kadmon Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Part of the Kadmon Pharmaceuticals discovery platform involves metabolomics, a focus of the PI's research. PI has stock options and serves on the scientific advisory board for which he is compensated. The aggregate of the PI's equity interest and scientific advisory board fee exceed the NIH threshold. The COI in Research Panel determined a potential for FCOI.
Mechanisms and consequences of metabolic manipulation by human cytomegalovirus
Human cytomegalovirus (HCMV) is a major cause of birth defects, a life-threatening opportunistic agent in immuno suppressed people, and a possible cofactor in certain cancers. The host metabolic environment is dramatically altered during infection with HCMV. The virus induces many metabolic pathways, with several lipid biosynthetic pathways essential for the production of virus progeny. We will explore the means by which the virus turns on these pathways, and the ways in which they contribute to viral replication. Our results will provide new insights into mechanisms underlying HCMV infection, information essential to our ultimate ability to develop new therapies and control infections.
Filed on August 14, 2015.
Tell us what you know about Joshua Rabinowitz's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Joshua Rabinowitz filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Joshua Rabinowitz | Princeton University | Conflict of Interest | Kadmon Corporation | $80,000 - $99,999 |
| Joshua Rabinowitz | Princeton University | Conflict of Interest | Colorado Research Partners | $80,000 - $99,999 |
| Joshua Rabinowitz | Princeton University | Conflict of Interest | Kadmon Pharmaceuticals | $20,000 - $39,999 |
| Joshua Rabinowitz | Princeton University | Conflict of Interest | Bantam Pharmaceuticals | $20,000 - $39,999 |
| Joshua Rabinowitz | Princeton University | Conflict of Interest | L.E.A.F. Pharmaceuticals | $10,000 - $19,999 |
| Joshua Rabinowitz | Princeton University | Conflict of Interest | Colorado Research Partners | Value cannot be readily determined |
| Joshua Rabinowitz | Princeton University | Conflict of Interest | Raze Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.